These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30408070)

  • 1. HIV 2-LTR experiment design optimization.
    Cannon L; Vargas-Garcia CA; Jagarapu A; Piovoso MJ; Zurakowski R
    PLoS One; 2018; 13(11):e0206700. PubMed ID: 30408070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach to parameter estimation in HIV dynamical models.
    Putter H; Heisterkamp SH; Lange JM; de Wolf F
    Stat Med; 2002 Aug; 21(15):2199-214. PubMed ID: 12210633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory Bayesian model selection for serial genetics data.
    Zhao JX; Foulkes AS; George EI
    Biometrics; 2005 Jun; 61(2):591-9. PubMed ID: 16011709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian estimation of HIV-1 dynamics in vivo.
    Ushakova A; Pettersen FO; Mæland A; Lindqvist BH; Kvale D
    Math Med Biol; 2015 Mar; 32(1):38-55. PubMed ID: 24078026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint modeling of longitudinal data and informative dropout time in the presence of multiple changepoints.
    Ghosh P; Ghosh K; Tiwari RC
    Stat Med; 2011 Mar; 30(6):611-26. PubMed ID: 21337357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker.
    Bushman F
    AIDS; 2003 Mar; 17(5):749-50. PubMed ID: 12646799
    [No Abstract]   [Full Text] [Related]  

  • 8. No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects.
    Visco-Comandini U; Yun Z; Vahlne A; Sönnerborg A
    AIDS Res Hum Retroviruses; 1999 May; 15(7):609-17. PubMed ID: 10331439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 and glucocorticoids synergistically induce human immunodeficiency virus type-1 expression in chronically infected U1 cells by a long terminal repeat independent post-transcriptional mechanism.
    Kinter AL; Biswas P; Alfano M; Justement JS; Mantelli B; Rizzi C; Gatti AR; Vicenzi E; Bressler P; Poli G
    Mol Med; 2001 Oct; 7(10):668-78. PubMed ID: 11713366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (ADP-ribose) polymerase is involved in PMA-induced activation of HIV-1 in U1 cells by modulating the LTR function.
    Kameoka M; Tanaka Y; Ota K; Itaya A; Yoshihara K
    Biochem Biophys Res Commun; 1999 Aug; 262(1):285-9. PubMed ID: 10448106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the Bayesian dynamic survival model in medicine.
    He J; McGee DL; Niu X
    Stat Med; 2010 Feb; 29(3):347-60. PubMed ID: 20014356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches.
    Trägårdh M; Chappell MJ; Ahnmark A; Lindén D; Evans ND; Gennemark P
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):207-21. PubMed ID: 26932466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 and HIV-2 produce different amounts of 2-long terminal repeat circular DNA in vitro.
    Gueudin M; Braun J; Plantier JC; Simon F
    AIDS; 2008 Nov; 22(18):2543-5. PubMed ID: 19005280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robustness considerations in Bayesian analysis.
    Gustafson P
    Stat Methods Med Res; 1996 Dec; 5(4):357-73. PubMed ID: 9004378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
    Leonard JN; Schaffer DV
    J Virol; 2005 Feb; 79(3):1645-54. PubMed ID: 15650190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment.
    Abbas I; Rovira J; Casanovas J
    Contemp Clin Trials; 2007 May; 28(3):220-31. PubMed ID: 16979387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of long-term HIV dynamic studies using semiparametric mixed-effects models.
    Huang Y; Park JG; Zhu Y
    Biom J; 2008 Aug; 50(4):528-40. PubMed ID: 18615413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accommodating uncertainty in a tree set for function estimation.
    Healy BC; DeGruttola VG; Hu C
    Stat Appl Genet Mol Biol; 2008; 7(1):Article5. PubMed ID: 18312210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 replication by the Cre-loxP hammerhead ribozyme.
    Habu Y; Miyano-Kurosaki N; Takeuchi H; Matsumoto N; Tamura Y; Takaku H
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):723-6. PubMed ID: 11563101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term suppression of HIV-1C virus production in human peripheral blood mononuclear cells by LTR heterochromatization with a short double-stranded RNA.
    Singh A; Palanichamy JK; Ramalingam P; Kassab MA; Bhagat M; Andrabi R; Luthra K; Sinha S; Chattopadhyay P
    J Antimicrob Chemother; 2014 Feb; 69(2):404-15. PubMed ID: 24022068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.